While there is hardly any doubt left that high cholesterol does no good to any one, a recent research has raised hopes of patients. Though there are drugs like statins which can cut off the risk of death due to the same, it has been found that it cannot save all patients with as many as 10% of the patients suffering from its negative consequences. In addition, there are many who are unable to get the chief benefit of the drug to lower down their LDL-C, or "bad cholesterol”.
Perhaps this is what made researchers to develop a new class of cholesterol-busting medication which could change the future course for patients. In the name of REGN727 under PCSK9 inhibitors, the drug could considerably reduce cholesterol by 65% in healthy ones. Another fascinating part of the drug was that it could reduce bad cholesterol by 61% in those who were already taking atorvastatin, a powerful cholesterol-lowering medication. With no side effects identified so far, there is need that this drug is being considered for the treatment.
If the lead author of the study, Dr. Evan Stein of the Metabolic and Atherosclerosis Research Center in Cincinnati, is to be heard, there are fair chances that this drug could surpass the benefits attached with popularly used statins in near future.
"Inhibitors of PCSK9 are perhaps the most exciting new approach to LDL-lowering based on very strong human genetics supporting the efficacy and safety of this approach”, said Dr. Dan Rader, a Professor of medicine at the University of Pennsylvania, who is also acting as a consultant for the pharmaceutical companies, Regeneron and Sanofi, which are supporting the study.
While the research published in the New England Journal of Medicine is being getting the attention of one and all, there are hopes raised that there might be some sort of effective replacement for statins developed in the time to come.
- Fire threatens entire city in Alberta
- Authorities order evacuation of entire city in Alberta due to wildfire
- Mitel Networks Corp of Canada to Buy Polycom Inc for Almost $2 Billion
- Reportedly Bombardier Inc. is Nearing a Deal with Delta for C Series Jetliners
- Review shows alcohol has no net health benefits